VolitionRx Participates in Launch of DETECSEPS Program in France

VolitionRx has launched the DETECSEPS consortium program in France to evaluate early sepsis detection using its Nu.Q NETs H3.1 biomarker alongside the IDS i10 automated analyzer and the NEWS2 clinical score, with results available within one hour. Volition is providing the assay pro bono for the AP-HP-led clinical evaluation and estimates an eventual multi-billion-dollar testing TAM based on approximately 166 million annual global sepsis cases. The initiative is an early-stage clinical validation and commercialization opportunity rather than a near-term revenue catalyst.

Analysis

This is validation-stage, not commercialization-stage, news for VNRX. Providing assays pro bono means there is no near-term revenue read-through; the economically relevant milestones are prospective-study performance, a defined clinical decision threshold incremental to NEWS2, and a reimbursement pathway. Without evidence that the marker changes admission/antibiotic decisions while reducing false negatives, the large theoretical testing market has little bearing on valuation.

RVTY has modest upside from incremental analyzer utilization but negligible group-level financial sensitivity. The more material competitive dynamic is that successful deployment on an installed automated platform lowers adoption friction for hospital laboratories, potentially making VNRX a consumable supplier rather than requiring dedicated-instrument capex; conversely, this leaves VNRX dependent on a much larger partner's commercial priorities and assay-placement economics.

Over the next 1-3 months, VNRX may attract retail interest around trial enrollment or interim communications, but a durable re-rating requires independently reported diagnostic metrics and an executable route to CE-IVD/other regulatory clearance plus payment. Over 6-18 months, even strong discrimination data can fail commercially if the test does not demonstrate net cost savings against existing workflows such as lactate, procalcitonin and clinical scoring. The contrarian view is that emergency-department triage is a high-bar workflow: a one-hour result is useful only if it arrives early enough to alter disposition and its negative predictive value supports safe discharge.

Key Decisions for Investors

• No core position in VNRX on this release; treat it as an event watch. Reassess only upon a peer-reviewed prospective dataset reporting sensitivity, specificity/NPV, AUC versus NEWS2 alone, sample size and pre-specified endpoint achievement.
• For biotech-event risk capital, consider a small VNRX long only after liquidity and cash runway are verified in the next filing; cap exposure at an amount consistent with binary diagnostic-validation risk. Exit on a material miss versus NEWS2, a delayed study timeline, or evidence of financing need before a commercial catalyst.
• Do not use RVTY as a direct expression of the thesis: any assay pull-through is immaterial relative to its diversified diagnostics base. Maintain RVTY exposure based on its broader diagnostics/reagent-cycle outlook, not this consortium.
• Monitor reimbursement and regulatory signals over 6-18 months: a health-economic result demonstrating fewer avoidable admissions without increased missed sepsis would be the first credible catalyst for VNRX revenue estimates; absence of such evidence should prevent assigning material sepsis TAM value.